The startup develops microbiome-based therapeutics utilizing a strain catalog of bacteria and fungi, along with a genomic database and computational platform for product development. This approach enables hospitals to access targeted medicinal drugs that enhance patient health and quality of life.
Funding
$27.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many age-related health conditions, such as bone loss and arthritis, are exacerbated by inflammation, and current treatments may not fully address the underlying microbial imbalances in the gut. Existing solutions often lack rigorous clinical validation and may not effectively target the root causes of these inflammatory disorders.
Solution
Solarea Bio develops clinically-validated medical foods using its Microscape Technology™ to isolate and identify beneficial microbes from edible plants. These microbes are formulated into Defined Microbial Assemblages (DMA™) that target inflammatory signals and strengthen the gut barrier. Solarea's products undergo in vitro, preclinical, and randomized, double-blind, placebo-controlled clinical food trials to ensure safety and efficacy in addressing age-related inflammatory disorders. The company's lead product, Bondia™, is clinically validated to slow bone loss in postmenopausal women, and additional products are in development for rheumatoid arthritis, psoriatic arthritis, and cellular aging.
Target Audience
The primary target audience includes individuals experiencing age-related inflammatory conditions such as bone loss, rheumatoid arthritis, and psoriatic arthritis, as well as healthcare professionals seeking clinically-validated medical food interventions.
Features
- Microscape Technology™ for isolating and sequencing microbes from fruits and vegetables
- Proprietary genomic database with over 5,000 microbial isolates and 16 million genes
- AI-driven in silico predictions to identify immunomodulatory candidates
- Defined Microbial Assemblages (DMA™) combining bacteria, fungi, and prebiotic plant fibers
- In vitro testing to assess gut barrier integrity and reduce inflammatory cytokine production
- Preclinical testing using gold-standard disease models to evaluate safety and efficacy
- Randomized, double-blind, placebo-controlled human clinical food trials for product validation
- Bondia™: Clinically validated to slow bone loss in early postmenopausal women
- SBD121: Undergoing clinical trials for the dietary management of rheumatoid arthritis